Tamsulosin Hydrochloride Capsule
Product Images NDC 71610-738

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 71610-738). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 0.4 mg (71610 0738 30)

Label for Tamsulosin Hydrochloride (Tamsulosin HCl), USP, 0.4 mg oral capsules, containing 30 capsules per container. The label includes storage instructions (20-25 degrees C), manufacturer information (Aurobindo Pharma Limited, Hyderabad, India), labeler (Aphena Pharma Solutions - Tennessee, LLC), and directions to keep out of reach of children. The product is marked for prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph illustrating mean plasma concentrations of Tamsulosin Hydrochloride over time after a single 0.4 mg capsule dose. It compares concentrations under fasted and fed conditions over 36 hours, with the fasted condition showing a higher peak concentration than the fed condition.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change on the y-axis and duration of treatment in weeks on the x-axis. The graph compares three treatment groups: 0.8 mg, 0.4 mg, and placebo. Data points show decreasing symptom scores over 13 weeks, with the 0.8 mg group showing the greatest mean reduction, followed by 0.4 mg, then placebo. Sample sizes for each time point are indicated below the x-axis.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean symptom score changes over a 13-week treatment period. The x-axis represents duration of treatment in weeks and the y-axis indicates mean change. Three groups are plotted: 0.8 mg, 0.4 mg, and placebo, illustrating the decline in symptom scores over time for each treatment group.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing the mean change in peak urine flow rate over a 13-week treatment period plus Last Observed Carry Forward (LOCF). The x-axis represents duration of treatment in weeks, the y-axis shows mean change in mL/sec from baseline. Three lines represent treatment groups: 0.8 mg, 0.4 mg, and placebo. The 0.8 mg and 0.4 mg groups show higher increases over time compared to placebo, which remains near baseline values.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in peak urine flow rate over a duration of treatment from 0 to 13 weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with markers and trend lines illustrating changes in flow rate (mL/sec) over the weeks of treatment.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure diagram of Tamsulosin Hydrochloride, showing its molecular arrangement including aromatic rings, functional groups, and hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.